Triamcinolone Acetonide (TAC) Injections with a New Needle-Free Drug-Delivery System (MedJet) in the Treatment of Patients with Primary Cutaneous Lymphoma Plaques
This clinical trial tests the administration of the steroid medication, TAC, using MedJet, a new needle-free drug-delivery system in patients with primary cutaneous lymphoma (cutaneous T-cell lymphoma [CTCL] and cutaneous B-cell lymphoma [CBCL]) who have areas of hard and thick skin (plaques) to determine if it is more effective, safe, and less painful than standard topical agents or needle steroid injections. Current National Comprehensive Cancer Network (NCCN) guidelines for primary cutaneous lymphomas recommend skin-directed therapies such as topical creams for early stage disease. However, topical therapies when applied locally and directly to lesions can have some side effects such as skin thinning, skin irritation, and skin sensitivity to the sun. These therapies can also be expensive and must be applied once or twice daily, which can be burdensome. For thicker lesions, topical therapies also may not penetrate well enough to be effective at resolving the lesion. Another treatment for cutaneous lymphoma is needle steroid injections. The benefits of steroid injections can be significant skin improvement, which can last for several months from just one treatment. However, needle injection usage can be limited due to pain, fear of needles, or too many plaques to treat in an office visit. A needle-less injection system could be a solution as the MedJet system uses compressed air instead of needles to penetrate the skin and deliver medication to the area of inflammation which may lead to better treatment satisfaction in patients with cutaneous lymphoma.